WORCESTER, MA – Grove Instruments Inc., a leading medical device company developing the world’s first noninvasive glucometer today announced that The United States Patent and Trademark Office (USPTO) has granted new U.S. Patent number 8175666 to Grove further protecting its core glucose measurement technology. “Allowance of these claims has already been granted in China, with approval pending in other PCT countries. This approval is key to protecting our core technology and methods here in the US,” commented Arthur Combs, Grove’s CEO.
Grove’s intellectual property (IP) portfolio of 9 issued patents is demonstrative of the Grove team’s record of continuous innovation. “Patents 8 and 9 are key for us as they speak directly to methods we employ today in our devices. Earlier patents were precedent setting and remain of historical interest,” said Combs. Over the past two years, Grove Instruments has expanded its patent portfolio, been awarded its 8th, 9th and 10th NIH NIDDK Grants through the SBIR program, closed Series B financing of $6 million, and last year was the recipient of an Accelerator Award from the Massachusetts Life Sciences Center.
“The last 9-12 months has been a time of solid productivity,” says Combs, “We spent the second half of 2011 designing and building our most advanced glucometer and completing a New England IRB clinical study. That study included 63 diabetic subjects and produced over 3,900 data pairs validating our noninvasive technology against the ISO 15197 Standard. For 2012, we believe that the data and analysis from that trial will result in seven 7 new patent applications, the first 2 of which have already been submitted.”
“We are proud of our Team’s accomplishments. Every day they solve difficult technical challenges, add to our intellectual property portfolio, and continue to bring our most advanced noninvasive glucometers to clinical validation.” concludes Combs. “2012 is going to be a year of tremendous achievement for Grove. The intellectual property portfolio is just one tangible measure of our continuous growth and achievement.”
About Grove Instruments
Grove Instruments, Inc. is a privately held pre-market medical device company developing the world’s first noninvasive glucometer with the potential to exceed the ISO standard for blood glucose meters. Grove’s patented technology is based on the seminal concept of the Optical Bridge and is unique among all NIR spectroscopic approaches to noninvasive blood glucose determination. The Company has been recognized for its innovation, technology development and clinical results on 10 separate occasions by the NIH NIDDK with funded SBIR Grants. In 2011, Grove was also recognized by the Massachusetts Life Sciences Center with an Accelerator Award – one of only 4 recipients out of all Boston-area life sciences companies applying in that round. For more information see www.groveinstruments.com or contact Arthur Combs (314 341 3444 mobile).
